Search the GHTC website

Twenty years after the approval of the first HPV vaccine, a game-changing tool that has helped dramatically reduce rates of HPV infection and cervical cancer around the world, researchers are now developing new tools to address remaining gaps in cervical cancer screening, diagnosis, and care.

November 16, 2026 by Hannah Sachs-Wetstone

The first HPV vaccine was approved 20 years ago, a game-changing tool that has helped dramatically reduce rates of HPV infection and cervical cancer around the world. Today, cervical cancer, which is primarily caused by HPV infection, is largely preventable thanks to advances in vaccination, screening, and diagnosis. Yet it remains the fifth most commonly diagnosed cancer among women globally and disproportionately affects low- and middle-income countries, where access to vaccination, screening, and treatment remains limited. 

Despite the availability of highly effective vaccines, ensuring they reach everyone who could benefit from them has remained a major global challenge. The World Health Organization’s recommendation supporting a single-dose HPV vaccination schedule for eligible age groups offers an important opportunity to expand coverage, particularly in resource-constrained settings, by reducing costs and simplifying delivery.

Expanding access to existing tools is only part of the solution. Researchers are also advancing innovative technologies that could make screening and diagnosis more accessible and help address longstanding treatment gaps through therapeutic vaccines.

Promising screening and diagnostic tools to improve access 

Although effective HPV screening and diagnostic technologies already exist, many require clinic visits and specialized equipment and can be costly to implement. Researchers are developing new approaches that aim to make screening faster, less invasive, and more accessible, particularly in low-resource settings globally.  

New artificial intelligence (AI)-powered screening and diagnostic tools could make cervical cancer detection more widely available by reducing the need for expensive equipment and highly trained clinicians. 

One early study evaluated a novel low-cost, portable, AI-powered microscope designed to detect high-risk cervical precancer in resource-constrained settings. Another study, conducted in five African countries, tested an inexpensive smartphone-based AI tool that analyzes images of the cervix to detect early signs of cervical cancer in less than a minute without an internet connection. 

Researchers are also exploring alternatives to traditional cervical sampling. One four-year study evaluated a diagnostic method using menstrual blood collected on a small cotton strip placed on a sanitary pad, offering a simpler, less-intrusive option for patients. Other non-invasive approaches, including urine-based tests, are also in development.

Together, these innovations reflect a shift toward more patient-centered, accessible approaches that could help overcome longstanding barriers to cervical cancer screening and diagnosis. 

Therapeutic vaccines, a new frontier in cervical cancer innovation 

Approximately 94 percent of global cervical cancer deaths occur in low- and middle-income countries, highlighting persistent gaps not only in prevention, screening, and diagnostic coverage, but also in treatment. Standard treatments, such as chemotherapy, radiation, and surgery, can be difficult to access in resource-limited settings around the world due to health infrastructure gaps, high costs, and other barriers.

Therapeutic vaccines, which are designed to treat disease rather than prevent it, could help address some of these obstacles. Unlike preventive HPV vaccines that stop infection before it occurs, therapeutic vaccines are designed to help the body target precancerous lesions before they become cancerous or target cancerous cells directly. As an alternative treatment for precancer or a complementary treatment to existing cancer therapies, they could help reduce reliance on more invasive treatments and expand access to care in low-resource settings.

Although no therapeutic vaccines are available yet, several promising candidates are in development. One of the most advanced is being developed to treat HPV-related cervical precancerous lesions and demonstrated encouraging results in a recently concluded Phase 3 trial. 

Another candidate showed promise in a recent Phase 2 trial when combined with standard-of-care chemoradiation in patients with locally advanced cervical cancer, in which the disease has spread beyond the cervix but not to distant organs. 

The promising progress of these candidates highlights growing efforts to improve global access to cervical cancer care, particularly in settings where access to specialized treatments remains limited. 

Innovating toward elimination 

Twenty years after the first HPV vaccine transformed cervical cancer prevention, researchers are continuing to develop new ways to address remaining gaps by directly targeting barriers to access. From AI-powered screening and diagnostic tools and less invasive sampling methods to therapeutic vaccines that could offer new treatment options, these innovations are designed with access in mind. 

But promising science alone will not eliminate cervical cancer. Realizing the potential of these innovations will require sustained investment across the research and development pipeline, from early discovery and clinical validation to regulatory approval, manufacturing, and equitable access. With continued investment and collaboration, these advances could help accelerate progress toward a future in which cervical cancer is no longer a public health threat. 

About the author

Hannah Sachs-WetstoneGHTC

Hannah supports advocacy and communications activities and member coordination for GHTC. Her role includes developing and disseminating digital communications, tracking member and policy news, engaging coalition members, and organizing meetings and events.Prior to joining GHTC,...read more about this author